Clinical Trials

 
 
 
If you are interested in any of the trials or think that you meet the criteria to participate, please call the Presence Cancer Care at 815-730-3098.
 
 
 
 

Biliary Tract

 
S1815 : First-Line Biliary Tract Cancers
A Phase III Randomized Trial Of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed Advanced Biliary Tract Cancers
 
 
 

Lung

 
A221504 : Advanced IIIB or IV advanced NSCL
A Randomized, Double-Blind, Placebo-Controlled Pilot Study Of An Oral, Selective Peripheral Opioid Receptor Antagonist In Advanced Non-Small Cell Lung Cancer (Adenocarcinoma)
 
NCT 02193282 CTSU/A151216 : NSCLC
Adjuvant Lung Cancer Enrichment Marker Identification & Sequencing Trial (ALCHEMIST)
 
ANAM 17-20 : Weightloss in NSCLC
A phase 3, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of anamorelin HCl for the treatment of malignancy associated weight loss and anorexia in adult patients with advanced non-small cell lung cancer (NSCLC)
 
EA5163 : Advanced Nonsquamous NSCLC
A Randomized, Phase III Study of Firstline Immunotherapy alone or in Combination with Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non‐Small Cell Lung Cancer (NSCLC) with Immunobiomarker SIGNature‐driven Analysis
 
 
 

Lymphoma

 
Relapsed/Refractory Hodgkin Lymphoma – E4412
A Study with an Expansion Cohort/Randomized Phase II Study of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma

 
 
 

Renal

 
E7080-G00-307 : Advanced Renal Cell
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination with Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects with Advanced Renal Cell Carcinoma
 
 
 
 
 

Blood

 
Connect AZA-MDS-006 : AML and MDS Registry
The Connect MDS and AML Disease Registry is a prospective, longitudinal, multi-center observational cohort study of patients with newly diagnosed MDS or AML Study
 
 
 

Melanoma

 
EA6134 : First-Line Metastatic Melanoma
A Randomized Phase III trial of Dabrafenib + Trametinib followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma
 
 
 

Prostate

 
EA8153 : 2nd line Metastatic Prostate
Cabazitaxel with Abiraterone Versus Abiraterone Alone Randomized Trial for Extensive Disease Following Docetaxel: The CHAARTED2 Trial
 
 
 

Various

 
Exact Sciences 2018-01 : Biomarkers on Solid Tumors
Blood Sample Collection to Evaluate Biomarkers in Subjects with Untreated Solid Tumors: Breast, Lung, Coorectal, Prostate, Bladder, Uterine, Kidney/Renal Pelvis, Pancreatic, Liver, Stomach, Ovarian or Esophageal
 
Observational: Risk of Febrile Neutopernia – 20170758 Amgen
A Prospective Observational Study to Estimate the Incidence of Febrile Neutropenia among Subjects with Non-myeloid Malignancies at High Risk for Febrile Neutropenia and receiving Neulasta® (pegfilgrastim) Onpro® kit or Other Physician Choice Options for Prophylaxis of Febrile Neutropenia
 
 
 
 
 

Breast

 
M14-239 : 2nd-Line NSCLC
Phase 2, Open-Label Safety and Efficacy Study of Telisotuzumab Vedotin (ABBV-399) in Subjects with Previously Treated c-Met+ Non-Small Cell Lung Cancer
 
A011502 : Adjuvant Breast
A randomized phase III double blinded placebo-controlled trial of aspirin as adjuvant therapy for HER2 negative breast cancer: the ABC trial
 
S1418 : Adjuvant Breast Triple Negative
A Randomized Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with = 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy
 
A5481082 : Observational: Hormone Receptor Positive Advanced Breast Cancer
Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Multicenter Non-Interventional Study
 
RAD1901-308 : Second-Line Advanced Breast Cancer
Elacestrant Monotherapy vs. Standard of Care for the Treatment of Patients with ER+/HER- Advanced Breast Cancer Following CDK4/6 Inhibitor Therapy: A Phase 3 Randomized, Open-Label, Active-Controlled, Multicenter Trial(EMERALD)
 
NRG- BR003 NCT 02488967 : Triple-Negative Invasive Breast Cancer
A Randomized Phase III Trial of Adjudavant Therapy Comparing Doxorubib Plus Cyclophosphanide Followed by Weekly Paclitaxel With or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer
 
NRG- BR004 : First-line HER2+ Metastatic Breast
A Randomized, Double-Blind, Phase III Trial of Paclitaxel/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer
 
 
 

Urothelial

 
1st-line Locally Advanced/Metastatic Urothelial Cancer – MK7902-011
A Phase 3, Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Lenvatinib (E7080/MK-7902) Versus Pembrolizumab and Matching Placebo as First Line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma in Cisplatin-ineligible Participants Whose Tumors Express PD-L1, and in Participants Ineligible for Any Platinum-containing Chemotherapy Regardless of PD-L1 Expression (LEAP-011)
 
 
 
 
 

Our Team

 
 
 

Medical Director of Clinical Research

 
Dr. Nafisa Burhani, MD
 
 
 
 
 

Manager of Clinical Research

 
Karen Sceniak, CCRC
ksceniak@jolietoncology.com
 
 
 
 
 

Clinical Research Coordinators

 
 
 
 
 

Data Manager

 
 
 
 
 

Regulatory Affairs Manager